Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRVS NASDAQ:EPIX NASDAQ:IFRX NASDAQ:XERS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$11.91$13.73$3.55▼$26.95$1.00B0.841.33 million shs1.98 million shsEPIXESSA Pharma$0.20$0.20$0.18▼$1.94$9.52M1.573.75 million shsN/AIFRXInflaRx$1.81-0.3%$1.96$0.74▼$2.95$130.85M2.421.16 million shs1.49 million shsXERSXeris Biopharma$6.95$6.29$4.40▼$10.08$1.20B0.781.57 million shs2.40 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals0.00%-0.17%-8.94%-10.65%+203.05%EPIXESSA Pharma0.00%0.00%0.00%0.00%-88.09%IFRXInflaRx0.00%+12.81%-26.92%+92.02%+126.19%XERSXeris Biopharma0.00%+2.36%+8.93%+27.76%+51.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRVSCorvus Pharmaceuticals$11.91$13.73$3.55▼$26.95$1.00B0.841.33 million shs1.98 million shsEPIXESSA Pharma$0.20$0.20$0.18▼$1.94$9.52M1.573.75 million shsN/AIFRXInflaRx$1.81-0.3%$1.96$0.74▼$2.95$130.85M2.421.16 million shs1.49 million shsXERSXeris Biopharma$6.95$6.29$4.40▼$10.08$1.20B0.781.57 million shs2.40 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRVSCorvus Pharmaceuticals0.00%-0.17%-8.94%-10.65%+203.05%EPIXESSA Pharma0.00%0.00%0.00%0.00%-88.09%IFRXInflaRx0.00%+12.81%-26.92%+92.02%+126.19%XERSXeris Biopharma0.00%+2.36%+8.93%+27.76%+51.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRVSCorvus Pharmaceuticals 2.71Moderate Buy$33.33179.88% UpsideEPIXESSA Pharma 1.00SellN/AN/AIFRXInflaRx 2.71Moderate Buy$7.00287.81% UpsideXERSXeris Biopharma 2.43Hold$10.8055.40% UpsideCurrent Analyst Ratings BreakdownLatest XERS, CRVS, EPIX, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2026IFRXInflaRx Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$7.00 ➝ $9.005/11/2026XERSXeris Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)5/11/2026IFRXInflaRx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $8.005/11/2026IFRXInflaRx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$2.00 ➝ $4.004/29/2026CRVSCorvus Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026IFRXInflaRx OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.00 ➝ $5.004/21/2026IFRXInflaRx GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.004/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.004/17/2026CRVSCorvus Pharmaceuticals The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.003/27/2026IFRXInflaRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRVSCorvus PharmaceuticalsN/AN/A$0.13 per share93.96$0.73 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$2.81 per shareN/AIFRXInflaRx$30K4,349.45N/AN/A$0.65 per share2.78XERSXeris Biopharma$291.85M4.11$0.10 per share69.38$0.08 per share86.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRVSCorvus Pharmaceuticals-$15.28M-$0.52N/AN/AN/AN/A-38.92%-35.75%8/6/2026 (Estimated)EPIXESSA Pharma-$28.54M-$0.56N/AN/AN/AN/A-21.71%-21.22%N/AIFRXInflaRx-$51.63M-$0.71N/AN/AN/AN/A-88.30%-65.77%8/6/2026 (Estimated)XERSXeris Biopharma$550K$0.06115.8320.44N/A3.81%735.00%3.24%8/6/2026 (Estimated)Latest XERS, CRVS, EPIX, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026CRVSCorvus Pharmaceuticals-$0.14-$0.15-$0.01-$0.15N/AN/A5/7/2026Q1 2026IFRXInflaRx-$0.17-$0.09+$0.08-$0.09$0.01 millionN/A5/7/2026Q1 2026XERSXeris Biopharma-$0.0027$0.01+$0.0127$0.01$79.83 million$83.13 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRVSCorvus PharmaceuticalsN/AN/AN/AN/AN/AEPIXESSA Pharma$1.69839.96%N/AN/A N/AIFRXInflaRxN/AN/AN/AN/AN/AXERSXeris BiopharmaN/AN/AN/AN/AN/ALatest XERS, CRVS, EPIX, and IFRX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/1/2100EPIXESSA Pharma--$1.698/25/20258/19/20258/22/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRVSCorvus PharmaceuticalsN/A19.8119.81EPIXESSA PharmaN/A69.0669.06IFRXInflaRxN/A4.164.16XERSXeris Biopharma17.002.121.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRVSCorvus Pharmaceuticals46.64%EPIXESSA Pharma75.12%IFRXInflaRx42.39%XERSXeris Biopharma42.75%Insider OwnershipCompanyInsider OwnershipCRVSCorvus Pharmaceuticals19.70%EPIXESSA Pharma15.50%IFRXInflaRx16.30%XERSXeris Biopharma4.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRVSCorvus Pharmaceuticals3084.09 million67.52 millionOptionableEPIXESSA Pharma5047.31 million39.98 millionOptionableIFRXInflaRx6072.29 million60.51 millionOptionableXERSXeris Biopharma290172.64 million165.13 millionOptionableXERS, CRVS, EPIX, and IFRX HeadlinesRecent News About These CompaniesIshara Investments LP Buys New Holdings in Xeris Biopharma Holdings, Inc. $XERSJune 18 at 6:29 AM | marketbeat.comXeris Biopharma Holdings, Inc. $XERS Stock Position Raised by Granahan Investment Management LLCJune 17, 2026 | marketbeat.comXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Hold" from BrokeragesJune 13, 2026 | americanbankingnews.comJim Cramer Blesses a Caller’s Speculative Investment in Xeris BiopharmaJune 12, 2026 | insidermonkey.comXeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®June 11, 2026 | businesswire.comXeris to retire $23M of convertible notes through exchange agreementsJune 11, 2026 | seekingalpha.comXeris Biopharma Announces Private Exchange of Convertible NotesJune 11, 2026 | finance.yahoo.comXeris Biopharma Announces Debt Reduction via Note ExchangesJune 11, 2026 | tipranks.comXeris Biopharma (NASDAQ:XERS) Director Sells $91,350.00 in StockJune 6, 2026 | insidertrades.comXeris Biopharma Shareholders Elect Directors and Ratify AuditorJune 5, 2026 | tipranks.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 SharesJune 3, 2026 | insidertrades.comXeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway RightMay 30, 2026 | seekingalpha.comUBS Group AG Reduces Position in Xeris Biopharma Holdings, Inc. $XERSMay 22, 2026 | marketbeat.comShareholders Will Be Pleased With The Quality of Xeris Biopharma Holdings' (NASDAQ:XERS) EarningsMay 15, 2026 | finance.yahoo.comXeris Biopharma Quality Draws Market Attention Through Growth SignalsMay 15, 2026 | kalkinemedia.comKResults: Xeris Biopharma Holdings, Inc. Confounded Analyst Expectations With A Surprise ProfitMay 9, 2026 | uk.finance.yahoo.comXeris Biopharma Holdings (XERS) Is Up 8.2% After Swing to Q1 Profitability - What's ChangedMay 8, 2026 | finance.yahoo.comXeris (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | aol.comAXeris Biopharma: Q1 Earnings SnapshotMay 7, 2026 | wtop.comWXeris Biopharma Reports First Quarter 2026 Financial ResultsMay 7, 2026 | finance.yahoo.comXeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXERS, CRVS, EPIX, and IFRX Company DescriptionsCorvus Pharmaceuticals NASDAQ:CRVS$11.91 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$12.15 +0.24 (+2.01%) As of 06/18/2026 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.ESSA Pharma NASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.InflaRx NASDAQ:IFRX$1.80 -0.01 (-0.28%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$1.81 +0.01 (+0.28%) As of 06/18/2026 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Xeris Biopharma NASDAQ:XERS$6.95 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$7.00 +0.05 (+0.78%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
